All In Biotech

Drug Trial Radar · NCT02180217

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Last checked: Nov 19, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Oct 6, 2014

Primary completion

Feb 21, 2018

Study completion Dec 4, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU. This is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period which evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease.

Conditions

  • Cushings Disease

Interventions

  • osilodrostatDrug

    Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.

  • LCI699 matching placeboDrug

    Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and StrataTime frame: Week 34 (8 weeks)

Locations

60 sites in 19 countries. Site status is shown where the registry gives one.

  • University of Colorado Hospital SC - LCI699C2301

    Aurora, Colorado

  • Emory University School of Medicine G2304 - C2301

    Atlanta, Georgia

  • Northwestern University SC - LCI699C2301

    Chicago, Illinois

  • The Johns Hopkins University School of Medicine Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital Neuroendocrine Unit

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Mount Sinai School of Medicine SC - LCI699C2301

    New York, New York

  • Columbia University Medical Center New York Presbyterian SC - LCI699C2301

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Oregon Health and Science University SC LCI699C2301

    Portland, Oregon

  • University of Pennsylvania Clinical Studies Unit Unniv SC

    Philadelphia, Pennsylvania

  • Medical College of Wisconsin MCW 2

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Cali, Colombia

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Erlangen, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Chandigarh, Punjab, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, India

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Messina, ME, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.